SC
SCLP.LSE Scancell Hldgs Plc
- Market cap
- GBX 117M
- P/E
- -
- P/B
- 8.89x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Apr 2026.
Is SCLP.LSE undervalued?
Graham numberThe Graham number of Scancell Hldgs Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scancell Hldgs Plc fundamental analysis
No fundamental analysis for Scancell Hldgs Plc yet.
Scancell Hldgs Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCI…
Full company profileScancell Hldgs Plc financial statements
Scancell Hldgs Plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 5.27M | 0.00 | 4.71M | 0.00 |
| Gross Profit | -32.6K | -27.6K | -21.1K | -43.0K | -249K | -740K | 4.75M | -966K | 3.59M | -672K |
| Operating Income | -4.55M | -4.94M | -6.73M | -6.78M | -9.75M | -14.3M | -11.9M | -18.3M | -15.0M | -17.4M |
| EBITDA | -4.46M | -4.91M | -6.69M | -6.73M | -14.9M | -3.76M | -12.2M | -7.06M | -12.7M | -16.8M |
| Net Income | -3.55M | -4.20M | -5.63M | -5.51M | -15.5M | -2.07M | -11.9M | -5.86M | -12.3M | -17.9M |
| EPS | -0.13 | -0.13 | -0.14 | -0.12 | -0.23 | -0.03 | -0.15 | -0.07 | -0.13 | -0.17 |
| Balance Sheet | ||||||||||
| Total Assets | 7.03M | 14.6M | 10.5M | 10.5M | 8.82M | 49.1M | 30.3M | 23.6M | 23.1M | 10.4M |
| Total Liabilities | 532K | 696K | 1.21M | 1.21M | 1.17M | 29.6M | 36.5M | 27.1M | 26.9M | 29.8M |
| Shareholders' Equity | 6.50M | 13.9M | 9.34M | 9.34M | 19.5M | 18.1M | -6.23M | -3.51M | -3.84M | -19.4M |
| Cash & Short-term Investments | 2.67M | 10.3M | 4.56M | 4.56M | 41.1M | 28.7M | 19.9M | 14.8M | 16.9M | 5.32M |
| Total Debt | - | - | - | 129K | 15.4M | 18.9M | 21.1M | 19.9M | 16.3M | 17.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.85M | -4.06M | -7.02M | -7.03M | -7.80M | -7.80M | -8.14M | -15.7M | -6.11M | -10.6M |
| Capital Expenditure | 61.1K | 11.4K | 2.66K | 2.66K | 27.0K | 744K | 203K | 177K | 14.0K | 94.0K |
| Free Cash Flow | -3.91M | -4.07M | -7.02M | -7.04M | -4.80M | -8.55M | -8.34M | -15.8M | -6.12M | -10.6M |
| Ratios | ||||||||||
| ROE | -54.5% | -30.1% | -60.3% | -59.0% | -79.4% | -11.4% | - | - | - | - |
| ROA | -50.4% | -28.7% | -53.4% | -52.2% | -175.5% | -4.2% | -39.4% | -24.9% | -53.1% | -172.8% |
| Net Profit Margin | - | - | - | - | - | - | -226.4% | - | -260.5% | - |
| Debt to Equity | - | - | - | 0.01x | 0.79x | 1.04x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scancell Hldgs Plc dividends
Scancell Hldgs Plc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Oct 21, 2026.
Who owns Scancell Hldgs Plc
- Insiders 3.13%
- Institutions 38.03%
- Public & others 58.84%
- Shares outstanding 136M
- Free float 64.8M
Scancell Hldgs Plc company profile
- Company name
- Scancell Hldgs Plc
- Ticker
- SCLP.LSE
- ISIN
- GB00B63D3314
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Fiscal year end
- April
- Address
- Bellhouse Building, Oxford, United Kingdom, OX4 4GD
- Phone
- 44 18 6558 2066
- Website
- scancell.co.uk
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+ that is in Phase III for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase III clinical trials for the treatment of solid tumors, including renal cell carcinoma, head, and neck; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company offers GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which promotes receptor clustering thereby improving immune signaling. Further, it provides pre-clinical products, such as SC129 and SC2811 for solid tumors; SC27; and GT 200 for ovarian cancer. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
Scancell Hldgs Plc management
10- Dr. Phillip John L'Huillier MBA, Ph.D.CEO & Director · born 1962
- Prof. Lindy Gillian Durrant Ph.D.Chief Scientific Officer, Director & Founder · born 1957
- Mr. David SchilanskyInterim Chief Financial Officer · born 1975
- Dr. Samantha Paston Ph.D.Head of Translational Research
- Dr. Mandeep SehmiHead of Business Development
- Dr. Callum ScotthasbeenSenior Vice President of Development
- Dr. Nermeen Varawalla DPHIL, M.B.A., M.D., Ph.D.Chief Medical Officer · born 1962
- Dr. Shamim Kazmi StokesHead of Programme Management
- Mr. Philip Angell-ManningHead of CMC
- Mr. Alex HaywardFinance Director & Company Secretary